Home/Pipeline/Brilinta (ticagrelor)

Brilinta (ticagrelor)

Cardiovascular disease

ApprovedCommercial

Key Facts

Indication

Cardiovascular disease

Phase

Approved

Status

Commercial

Company

AstraZeneca

About AstraZeneca

AstraZeneca is one of the world's largest pharmaceutical companies, headquartered in Cambridge, UK, with a market capitalization of approximately $285 billion. The company focuses on transformative science including next-generation therapeutics, AI-driven drug discovery, and personalized medicine approaches. AstraZeneca reported strong commercial performance in 2025 with 16 positive Phase 3 study results announced during the year, demonstrating continued pipeline strength across multiple therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Respiratory Metabolic Diseases Immunology Rare Diseases

Other Cardiovascular disease Drugs

Drug	Company	Phase	Status
NLRP3 inhibitor	Novo Nordisk	Phase 1	Active
Lipitor	Viatris	Approved	Commercial
Alnylam Collaboration Targets	Tenaya Therapeutics	Discovery/Research	Research Stage
ECO Synthesis® siRNA (Cardiovascular Partner Program)	Codexis	Preclinical	Active